ArticlePediatric nephrology (Berlin, Germany)2025
Clinical differences between female monozygotic twins with X-linked Alport syndrome with somatic mosaicism.
Article in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Although female patients with X-linked Alport syndrome (XLAS) have a generally milder prognosis than male counterparts, some female patients show poor prognosis. The clinically observed variation in the severity of female XLAS is thought to be due mainly to X chromosome inactivation (XCI) or modifier gene variants. We describe herein a 4-year-old female patient with persistent hematuria and proteinuria whose monozygotic, twin sister had no apparent abnormality on urinalysis. A kidney biopsy of the patient found the typical pattern of female XLAS. Genetic testing revealed a de novo pathogenic variant of COL4 A5 with somatic mosaicism. However, additional tests revealed that the asymptomatic twin sister had the same COL4 A5 variant with somatic mosaicism, and that the twins had the same ratio of somatic mosaicism and XCI. Moreover, targeted exome sequencing found no other modifier gene variants, suggesting that the severity of female XLAS depends on distinct but unknown factors in addition to the XCI and modifier gene variants. The findings of the present report emphasize the need to identify the hidden factors affecting the severity of Alport syndrome.
Indexed as
Identifiers
40299036What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.